pI: 10.9227 |
Length (AA): 149 |
MW (Da): 16998 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_126930)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G09990 | 40S ribosomal protein S16-1 |
Arabidopsis thaliana | AT3G04230 | 40S ribosomal protein S16-2 |
Arabidopsis thaliana | AT5G18380 | 40S ribosomal protein S16-3 |
Babesia bovis | BBOV_IV005360 | ribosomal protein S16, putative |
Brugia malayi | Bm1_14095 | 40S ribosomal protein S16 |
Caenorhabditis elegans | CELE_T01C3.6 | Protein RPS-16 |
Cryptosporidium hominis | Chro.20313 | 40S ribosomal protein S16 |
Cryptosporidium parvum | cgd2_3000 | 40S ribosomal protein S16 |
Dictyostelium discoideum | DDB_G0284093 | 40S ribosomal protein S16 |
Drosophila melanogaster | Dmel_CG4046 | Ribosomal protein S16 |
Echinococcus granulosus | EgrG_000821300 | 40S ribosomal protein S16 |
Entamoeba histolytica | EHI_008010 | 40S ribosomal protein S16, putative |
Entamoeba histolytica | EHI_131190 | 40S ribosomal protein S16, putative |
Entamoeba histolytica | EHI_160990 | 40S ribosomal protein S16, putative |
Entamoeba histolytica | EHI_038620 | 40S ribosomal protein S16, putative |
Echinococcus multilocularis | EmuJ_000821300 | 40S ribosomal protein S16 |
Giardia lamblia | GL50803_4652 | Ribosomal protein S16 |
Homo sapiens | ENSG00000105193 | ribosomal protein S16 |
Leishmania braziliensis | LbrM.26.0890 | 40S ribosomal protein S16, putative |
Leishmania braziliensis | LbrM.26.0900 | 40S ribosomal protein S16, putative |
Leishmania donovani | LdBPK_260840.1 | 40S ribosomal protein S16, putative |
Leishmania infantum | LinJ.26.0850 | 40S ribosomal protein S16, putative |
Leishmania infantum | LinJ.26.0840 | 40S ribosomal protein S16, putative |
Leishmania major | LmjF.26.0890 | 40S ribosomal protein S16, putative |
Leishmania major | LmjF.26.0880 | 40S ribosomal protein S16, putative |
Leishmania mexicana | LmxM.26.0880 | 40S ribosomal protein S16, putative |
Leishmania mexicana | LmxM.26.0890 | 40S ribosomal protein S16, putative |
Loa Loa (eye worm) | LOAG_11689 | 40S ribosomal protein S16 |
Mus musculus | ENSMUSG00000037563 | ribosomal protein S16 |
Mus musculus | 100862433 | 40S ribosomal protein S16-like |
Neospora caninum | NCLIV_024880 | 30S ribosomal protein S9P, related |
Oryza sativa | 4351374 | Os12g0124200 |
Oryza sativa | 4349653 | Os11g0127900 |
Plasmodium berghei | PBANKA_1423600 | 40S ribosomal protein S16, putative |
Plasmodium falciparum | PF3D7_0813900 | 40S ribosomal protein S16, putative |
Plasmodium knowlesi | PKNH_1426400 | 40S ribosomal protein S16, putative |
Plasmodium vivax | PVX_123075 | 40S ribosomal protein S16, putative |
Plasmodium yoelii | PY06464 | ribosomal protein S9 |
Saccharomyces cerevisiae | YDL083C | ribosomal 40S subunit protein S16B |
Saccharomyces cerevisiae | YMR143W | ribosomal 40S subunit protein S16A |
Schistosoma japonicum | Sjp_0035120 | ko:K02960 small subunit ribosomal protein S16e, putative |
Schistosoma mansoni | Smp_119920 | ribosomal protein S9 |
Schmidtea mediterranea | mk4.006836.02 | 40S ribosomal protein S16 |
Schmidtea mediterranea | mk4.008780.02 | 40S ribosomal protein S16 |
Trypanosoma brucei gambiense | Tbg972.7.1000 | 40S ribosomal protein S16, putative |
Trypanosoma brucei gambiense | Tbg972.7.990 | 40S ribosomal protein S16, putative |
Trypanosoma brucei | Tb927.7.1040 | 40S ribosomal protein S16, putative |
Trypanosoma brucei | Tb927.7.1050 | 40S ribosomal protein S16, putative |
Trypanosoma congolense | TcIL3000_7_750 | 40S ribosomal protein S16, putative |
Trypanosoma cruzi | TcCLB.503899.30 | 40S ribosomal protein S16, putative |
Trypanosoma cruzi | TcCLB.507513.60 | 40S ribosomal protein S16, putative |
Trypanosoma cruzi | TcCLB.503899.20 | 40S ribosomal protein S16, putative |
Trypanosoma cruzi | TcCLB.507513.70 | 40S ribosomal protein S16, putative |
Toxoplasma gondii | TGME49_263040 | ribosomal protein RPS16 |
Theileria parva | TP01_0200 | 40S ribosomal protein S16, putative |
Trichomonas vaginalis | TVAG_036300 | ribosomal protein S9, putative |
Trichomonas vaginalis | TVAG_094760 | ribosomal protein S9, putative |
Trichomonas vaginalis | TVAG_036220 | ribosomal protein S9, putative |
Trichomonas vaginalis | TVAG_020040 | ribosomal protein S9, putative |
Trichomonas vaginalis | TVAG_156650 | ribosomal protein S9, putative |
Trichomonas vaginalis | TVAG_177920 | ribosomal protein S9, putative |
Trichomonas vaginalis | TVAG_182810 | ribosomal protein S9, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.1040 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.1040 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.1040 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.7.1040 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_T01C3.6 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_T01C3.6 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_T01C3.6 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_1423600 | Plasmodium berghei | Essential | plasmo |
TGME49_263040 | Toxoplasma gondii | Probably essential | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.